P2.10. ALKTERNATE: A Pilot Study Alternating Lorlatinib with Crizotinib in Patients with ALK+ NSCLC and ALK-inhibitor Resistance - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Malinda Itchins
Meta Tag
Speaker Malinda Itchins
Topic Metastatic NSCLC: Targeted Therapy - FUSIONS
Keywords
ALKTERNATE
lorlatinib
crizotinib
ALK NSCLC
ALK-inhibitor resistance
targeted therapies
non-small cell lung cancer
progression-free survival
overall survival
ctDNA analysis
Powered By